<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312282</url>
  </required_header>
  <id_info>
    <org_study_id>ODO-TE-S101</org_study_id>
    <nct_id>NCT04312282</nct_id>
  </id_info>
  <brief_title>The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odonate Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odonate Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-cohort, multicenter, Phase 1 study of the effect of tesetaxel, an
      investigational, orally administered taxane, on the corrected QT (QTc) interval and the
      potential effect of food, a cytochrome P450 (CYP) 3A inhibitor (itraconazole), and a CYP3A
      inducer (rifampin) on tesetaxel pharmacokinetics (PK) in adult patients with advanced solid
      tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohort 1:

      Cohort 1 is a 2-period, 2-sequence, crossover study designed to assess the effect of food on
      the PK of tesetaxel and tesetaxel metabolites. Patients will be randomized in a 1:2 ratio to
      receive tesetaxel on Day 1 of two 21-day cycles under fed and fasting conditions in one of
      two opposing sequences (Sequence 1A and Sequence 1B).

      Cohort 2:

      Cohort 2 is a 2-period, single-sequence, crossover study designed to assess the potential PK
      drug-drug interaction (DDI) of a strong CYP3A inhibitor (itraconazole) on tesetaxel and
      tesetaxel metabolites. Patients will receive tesetaxel during Cycle 1 followed by a reduced
      dose of tesetaxel plus itraconazole during Cycle 2.

      Cohort 3:

      Cohort 3 is a 2-period, single-sequence, crossover study designed to assess the potential PK
      DDI of a strong CYP3A inducer (rifampin) on tesetaxel and tesetaxel metabolites. Patients
      will receive tesetaxel during Cycle 1 followed by tesetaxel plus rifampin during Cycle 2.

      Patients in all cohorts will also participate in a study designed to assess the effect of
      tesetaxel and tesetaxel metabolites on cardiac repolarization as measured by the change from
      baseline in the QTc interval over the first cycle of treatment. Patients who are tolerating
      and benefitting from treatment with tesetaxel will have the opportunity to continue onto an
      optional treatment extension.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cohorts: The change from baseline in Fridericia's corrected QT (ΔQTcF) interval</measure>
    <time_frame>Approximately 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1, Sequences 1A and 1B: Maximum observed plasma concentration (Cmax) for tesetaxel under fed and fasted conditions</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1, Sequences 1A and 1B: Area under the plasma concentration-time curve from 0 to the last measurable plasma concentration (AUC0-t) for tesetaxel under fed and fasted conditions</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: Cmax for tesetaxel in the presence and absence of itraconazole</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: AUC from 0 to 336 hours (AUC0-336h) for tesetaxel in the presence and absence of itraconazole</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3: Cmax for tesetaxel in the presence and absence of rifampin</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3: AUC0-336h for tesetaxel in the presence and absence of rifampin</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Cmax for tesetaxel metabolites</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: AUC for tesetaxel metabolites</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cohorts: Treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs)</measure>
    <time_frame>Baseline through 30 days after last administration of Study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Sequence 1A: Fed then fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fed conditions
Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Sequence 1B: Fasted then fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions
Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Tesetaxel plus itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Tesetaxel on Day 1 of a 21-day cycle
Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and itraconazole on Day -3 through Day 14 of a 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Tesetaxel plus rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Tesetaxel on Day 1 of a 21-day cycle
Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and rifampin on Day -6 through Day 14 of a 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Tesetaxel orally once every 3 weeks (Q3W)</description>
    <arm_group_label>Cohort 1, Sequence 1A: Fed then fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Tesetaxel orally Q3W</description>
    <arm_group_label>Cohort 1, Sequence 1B: Fasted then fed</arm_group_label>
    <arm_group_label>Cohort 2: Tesetaxel plus itraconazole</arm_group_label>
    <arm_group_label>Cohort 3: Tesetaxel plus rifampin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole orally QD from Day -3 to Day 14 of a 21-day cycle</description>
    <arm_group_label>Cohort 2: Tesetaxel plus itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Rifampin orally QD from Day -6 to Day 14 of a 21-day cycle</description>
    <arm_group_label>Cohort 3: Tesetaxel plus rifampin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male patients at least 18 years of age

          -  Histologically or cytologically confirmed solid tumor

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

          -  Adequate cardiac conduction by ECG

          -  Adequate bone marrow, hepatic, and renal function

        Exclusion Criteria:

          -  Presence of risk factors for QTc prolongation

          -  Presence of neuropathy Grade &gt; 1

          -  Anticancer treatment ≤ 14 days prior to randomization

          -  Major surgery ≤ 28 days prior to randomization

          -  Less than 2 weeks or 5 plasma half-lives (whichever is greater) since last use of:

               -  A moderate or strong inhibitor or inducer of CYP3A

               -  A CYP3A substrate with a narrow therapeutic range or that is contraindicated with
                  either itraconazole or rifampin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph O'Connell, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Odonate Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stew Kroll</last_name>
    <phone>650-576-9679</phone>
    <email>skroll@odonate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tesetaxel</keyword>
  <keyword>itraconazole</keyword>
  <keyword>rifampin</keyword>
  <keyword>food effect</keyword>
  <keyword>QTc interval</keyword>
  <keyword>food-drug interaction</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>PK</keyword>
  <keyword>tesetaxel metabolites</keyword>
  <keyword>advanced solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

